{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T21:17:52Z","timestamp":1778879872550,"version":"3.51.4"},"reference-count":67,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.cld.2025.12.001","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T12:33:18Z","timestamp":1773059598000},"page":"271-288","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association of Metabolic Dysfunction-Associated Steatohepatitis with Metabolic-Related Diseases"],"prefix":"10.1016","volume":"30","author":[{"given":"Leonidas","family":"Diamantopoulos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markos","family":"Kalligeros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott D.","family":"Isaacs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Didac","family":"Mauricio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.cld.2025.12.001_bib1","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.cld.2025.12.001_bib2","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL\u2013EASD\u2013EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","author":"Tacke","year":"2024","journal-title":"J Hepatol"},{"issue":"10","key":"10.1016\/j.cld.2025.12.001_bib3","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1016\/j.cgh.2024.03.006","article-title":"The global epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among patients with type 2 diabetes","volume":"22","author":"Younossi","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"Suppl","key":"10.1016\/j.cld.2025.12.001_bib4","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.3350\/cmh.2024.0431","article-title":"Epidemiology of metabolic dysfunction-associated steatotic liver disease","volume":"31","author":"Younossi","year":"2025","journal-title":"Clin Mol Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2025.12.001_bib5","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2025.12.001_bib6","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jhep.2022.11.010","article-title":"A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes","volume":"78","author":"Ajmera","year":"2023","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2025.12.001_bib7","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2337\/dc20-1997","article-title":"Advanced liver fibrosis is common in patients with type 2 diabetes followed in the outpatient setting: the need for systematic screening","volume":"44","author":"Lomonaco","year":"2021","journal-title":"Diabetes Care"},{"issue":"24","key":"10.1016\/j.cld.2025.12.001_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12247617","article-title":"Clinical predictive score for identifying metabolic dysfunction-associated steatotic liver disease in individuals with prediabetes using transient elastography","volume":"12","author":"Mahachai","year":"2023","journal-title":"J Clin Med"},{"issue":"3","key":"10.1016\/j.cld.2025.12.001_bib9","doi-asserted-by":"crossref","first-page":"e573","DOI":"10.1016\/j.cgh.2021.02.030","article-title":"Estimating global prevalence of metabolic dysfunction-associated fatty liver disease in overweight or Obese adults","volume":"20","author":"Liu","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2025.12.001_bib10","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S2468-1253(22)00317-X","article-title":"Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis","volume":"8","author":"Quek","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2025.12.001_bib11","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.cld.2025.12.001_bib12","first-page":"S10","article-title":"Pathogenesis of MASLD and MASH - role of insulin resistance and lipotoxicity","volume":"59","author":"Bansal","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.cld.2025.12.001_bib13","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.tips.2017.04.004","article-title":"Roles of diacylglycerols and ceramides in hepatic insulin resistance","volume":"38","author":"Petersen","year":"2017","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.cld.2025.12.001_bib14","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.freeradbiomed.2020.02.025","article-title":"Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease","volume":"152","author":"Chen","year":"2020","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.cld.2025.12.001_bib15","article-title":"The NLRP3 inflammasome in non-alcoholic fatty liver disease and steatohepatitis: therapeutic targets and treatment","volume":"13","author":"Yu","year":"2022","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.cld.2025.12.001_bib16","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000518407","article-title":"The role of innate immune cells in nonalcoholic fatty liver disease","volume":"14","author":"Nati","year":"2022","journal-title":"J Innate Immun"},{"issue":"1","key":"10.1016\/j.cld.2025.12.001_bib17","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jhep.2009.03.008","article-title":"Kupffer cells in non-alcoholic fatty liver disease: the emerging view","volume":"51","author":"Baffy","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2025.12.001_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2024.1444198","article-title":"Targeting hepatic macrophages for non-alcoholic fatty liver disease therapy","volume":"12","author":"Tian","year":"2024","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.cld.2025.12.001_bib19","first-page":"221","article-title":"Molecular pathways in non-alcoholic fatty liver disease","volume":"7","author":"Berlanga","year":"2014","journal-title":"Clin Exp Gastroenterol"},{"issue":"1","key":"10.1016\/j.cld.2025.12.001_bib20","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/iid3.391","article-title":"Inflammation initiates a vicious cycle between obesity and nonalcoholic fatty liver disease","volume":"9","author":"Luo","year":"2021","journal-title":"Immun Inflamm Dis"},{"key":"10.1016\/j.cld.2025.12.001_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.967375","article-title":"The role of FGF21 and its analogs on liver associated diseases","volume":"9","author":"Falamarzi","year":"2022","journal-title":"Front Med"},{"issue":"11","key":"10.1016\/j.cld.2025.12.001_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/cells8111419","article-title":"TGF-\u03b2 in hepatic stellate cell activation and liver fibrogenesis-updated 2019","volume":"8","author":"Dewidar","year":"2019","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.cld.2025.12.001_bib23","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/S0168-8278(02)00102-2","article-title":"Leptin is essential for the hepatic fibrogenic response to chronic liver injury","volume":"37","author":"Leclercq","year":"2002","journal-title":"J Hepatol"},{"issue":"7","key":"10.1016\/j.cld.2025.12.001_bib24","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9070762","article-title":"Role of leptin in non-alcoholic fatty liver disease","volume":"9","author":"Jim\u00e9nez-Cortegana","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.cld.2025.12.001_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110785","article-title":"The effect of adiponectin in the pathogenesis of non-alcoholic fatty liver disease (NAFLD) and the potential role of polyphenols in the modulation of adiponectin signaling","volume":"131","author":"Shabalala","year":"2020","journal-title":"Biomed Pharmacother"},{"issue":"7","key":"10.1016\/j.cld.2025.12.001_bib26","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.2337\/dci24-0094","article-title":"Metabolic dysfunction-associated steatotic liver disease (MASLD) in people with diabetes: the need for screening and early intervention. A consensus report of the American diabetes Association","volume":"48","author":"Cusi","year":"2025","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.cld.2025.12.001_bib27","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1053\/j.gastro.2025.02.044","article-title":"Global consensus recommendations for metabolic dysfunction-associated steatotic liver disease and steatohepatitis","volume":"169","author":"Younossi","year":"2025","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.cld.2025.12.001_bib28","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","volume":"28","author":"Cusi","year":"2022","journal-title":"Endocr Pract"},{"issue":"4","key":"10.1016\/j.cld.2025.12.001_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003100","article-title":"Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of population-based observational studies","volume":"17","author":"Jarvis","year":"2020","journal-title":"PLoS Med"},{"key":"10.1016\/j.cld.2025.12.001_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2023.155642","article-title":"Nonalcoholic fatty liver disease (NAFLD) and associated mortality in individuals with type 2 diabetes, pre-diabetes, metabolically unhealthy, and metabolically healthy individuals in the United States","volume":"146","author":"Golabi","year":"2023","journal-title":"Metabolism"},{"key":"10.1016\/j.cld.2025.12.001_bib31","article-title":"Established and emerging factors affecting the progression of nonalcoholic fatty liver disease","volume":"111s","author":"Kechagias","year":"2020","journal-title":"Metabolism"},{"issue":"13","key":"10.1016\/j.cld.2025.12.001_bib32","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000010214","article-title":"Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD)","volume":"97","author":"Golabi","year":"2018","journal-title":"Medicine (Baltim)"},{"issue":"1","key":"10.1016\/j.cld.2025.12.001_bib33","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2337\/cd18-0026","article-title":"Patients with lean nonalcoholic fatty liver disease are metabolically abnormal and have a higher risk for mortality","volume":"37","author":"Golabi","year":"2019","journal-title":"Clin Diabetes"},{"issue":"2","key":"10.1016\/j.cld.2025.12.001_bib34","doi-asserted-by":"crossref","first-page":"283","DOI":"10.2337\/dc19-1113","article-title":"Economic and clinical burden of nonalcoholic steatohepatitis in patients with type 2 diabetes in the U.S","volume":"43","author":"Younossi","year":"2020","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.cld.2025.12.001_bib35","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1186\/s12916-025-04320-7","article-title":"Effects of mediterranean diet, exercise, and their combination on body composition and liver outcomes in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis of randomized controlled trials","volume":"23","author":"Arita","year":"2025","journal-title":"BMC Med"},{"key":"10.1016\/j.cld.2025.12.001_bib36","doi-asserted-by":"crossref","unstructured":"Tacke F, Horn P, Wai-Sun Wong V, Ratziu V, Bugianesi E, Francque S, et al. EASL\u2013EASD\u2013EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). Journal of Hepatology. 2024;81(3):492-542.","DOI":"10.1016\/j.jhep.2024.04.031"},{"issue":"5","key":"10.1016\/j.cld.2025.12.001_bib37","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.ajcnut.2024.08.031","article-title":"Efficacy of lifestyle weight loss interventions on regression to normoglycemia and progression to type 2 diabetes in individuals with prediabetes: a systematic review and pairwise and dose-response meta-analyses","volume":"120","author":"Jayedi","year":"2024","journal-title":"Am J Clin Nutr"},{"issue":"121","key":"10.1016\/j.cld.2025.12.001_bib38","first-page":"13","article-title":"Pioglitazone: mechanism of action","author":"Smith","year":"2001","journal-title":"Int J Clin Pract Suppl"},{"issue":"22","key":"10.1016\/j.cld.2025.12.001_bib39","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa060326","article-title":"A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis","volume":"355","author":"Belfort","year":"2006","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.cld.2025.12.001_bib40","doi-asserted-by":"crossref","first-page":"305","DOI":"10.7326\/M15-1774","article-title":"Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial","volume":"165","author":"Cusi","year":"2016","journal-title":"Ann Intern Med"},{"issue":"18","key":"10.1016\/j.cld.2025.12.001_bib41","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.cld.2025.12.001_bib42","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like Peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab"},{"issue":"1","key":"10.1016\/j.cld.2025.12.001_bib43","doi-asserted-by":"crossref","first-page":"4947","DOI":"10.1038\/s41598-025-89408-z","article-title":"Glucagon-like peptide-1 receptor agonists improve metabolic dysfunction-associated steatotic liver disease outcomes","volume":"15","author":"Havranek","year":"2025","journal-title":"Sci Rep"},{"issue":"10019","key":"10.1016\/j.cld.2025.12.001_bib44","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.cld.2025.12.001_bib45","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.cld.2025.12.001_bib46","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.cld.2025.12.001_bib47","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.cld.2025.12.001_bib48","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa2401755","article-title":"A phase 2 randomized trial of survodutide in MASH and fibrosis","volume":"391","author":"Sanyal","year":"2024","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.cld.2025.12.001_bib49","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1038\/s41591-024-03018-2","article-title":"Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial","volume":"30","author":"Sanyal","year":"2024","journal-title":"Nat Med"},{"issue":"1\u20133","key":"10.1016\/j.cld.2025.12.001_bib50","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ejphar.2013.05.014","article-title":"Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice","volume":"715","author":"Tahara","year":"2013","journal-title":"Eur J Pharmacol"},{"issue":"16","key":"10.1016\/j.cld.2025.12.001_bib51","doi-asserted-by":"crossref","first-page":"9116","DOI":"10.1073\/pnas.161284298","article-title":"A glucose-responsive transcription factor that regulates carbohydrate metabolism in the liver","volume":"98","author":"Yamashita","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"Suppl 2","key":"10.1016\/j.cld.2025.12.001_bib52","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1463-1326.2010.01275.x","article-title":"Hepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP-1c","volume":"12","author":"Ferr\u00e9","year":"2010","journal-title":"Diabetes Obes Metabol"},{"issue":"2","key":"10.1016\/j.cld.2025.12.001_bib53","doi-asserted-by":"crossref","first-page":"298","DOI":"10.2337\/dc19-0641","article-title":"Empagliflozin effectively lowers liver fat content in well-controlled type 2 diabetes: a randomized, double-blind, phase 4, placebo-controlled trial","volume":"43","author":"Kahl","year":"2020","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.cld.2025.12.001_bib54","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s00125-018-4675-2","article-title":"Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study","volume":"61","author":"Eriksson","year":"2018","journal-title":"Diabetologia"},{"issue":"2","key":"10.1016\/j.cld.2025.12.001_bib55","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/dom.13520","article-title":"Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease","volume":"21","author":"Shimizu","year":"2019","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.cld.2025.12.001_bib56","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-083735","article-title":"Effect of dapagliflozin on metabolic dysfunction-associated steatohepatitis: multicentre, double blind, randomised, placebo controlled trial","volume":"389","author":"Lin","year":"2025","journal-title":"Bmj"},{"issue":"9","key":"10.1016\/j.cld.2025.12.001_bib57","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1136\/gutjnl-2020-320622","article-title":"NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications","volume":"69","author":"Targher","year":"2020","journal-title":"Gut"},{"issue":"8","key":"10.1016\/j.cld.2025.12.001_bib58","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1001\/jama.2022.13044","article-title":"Statin use for the primary prevention of cardiovascular disease in adults: US preventive services task force recommendation statement","volume":"328","author":"Mangione","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.cld.2025.12.001_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103431","article-title":"Age-specific protective effects of statins against cirrhosis in patients with chronic liver enzyme elevation associated with metabolic dysfunction: a retrospective cohort study of electronic health records","volume":"87","author":"Suzuki","year":"2025","journal-title":"eClinicalMedicine"},{"issue":"1","key":"10.1016\/j.cld.2025.12.001_bib60","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2337\/dsi23-0015","article-title":"Nonalcoholic fatty liver disease in diabetes: a call to action","volume":"37","author":"Cusi","year":"2024","journal-title":"Diabetes Spectr"},{"issue":"12","key":"10.1016\/j.cld.2025.12.001_bib61","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s11892-019-1269-4","article-title":"Bariatric surgery in the treatment of type 2 diabetes","volume":"19","author":"Affinati","year":"2019","journal-title":"Curr Diabetes Rep"},{"issue":"4","key":"10.1016\/j.cld.2025.12.001_bib62","first-page":"O1","volume":"28","author":"Mechanick","year":"2020","journal-title":"Obesity Medicine Association, and American Society of Anesthesiologists. Obesity (Silver Spring)"},{"issue":"1 Suppl 1","key":"10.1016\/j.cld.2025.12.001_bib63","first-page":"S167","article-title":"8. Obesity and weight management for the prevention and treatment of type 2 diabetes: standards of care in diabetes-2025","volume":"48","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cld.2025.12.001_bib64","article-title":"Bariatric surgery for metabolic dysfunction-associated steatotic liver disease (MASLD): current knowledge of mechanisms","author":"Liu","year":"2025","journal-title":"Hepatology"},{"issue":"21","key":"10.1016\/j.cld.2025.12.001_bib65","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.3390\/jcm10215019","article-title":"What do we know about inequalities in NAFLD distribution and outcomes? A scoping review","volume":"10","author":"Talens","year":"2021","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.cld.2025.12.001_bib66","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1093\/jn\/nxz212","article-title":"Food insecurity may be an independent risk factor associated with nonalcoholic fatty liver disease among low-income adults in the United States","volume":"150","author":"Golovaty","year":"2020","journal-title":"J Nutr"},{"issue":"8","key":"10.1016\/j.cld.2025.12.001_bib67","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.2337\/dc18-0165","article-title":"Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT trial)","volume":"41","author":"Kuchay","year":"2018","journal-title":"Diabetes Care"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326125001035?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326125001035?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T20:58:10Z","timestamp":1778878690000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326125001035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":67,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1089326125001035"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2025.12.001","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of Metabolic Dysfunction-Associated Steatohepatitis with Metabolic-Related Diseases","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2025.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}